RecruitingPHASE1, PHASE2NCT06844214
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Studying Proximal myotonic myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- SAR446268(biological)
- Enrollment
- 32 enrolled
- Eligibility
- 10-50 years · All sexes
- Timeline
- 2025 – 2029
Study locations (8)
- University of Florida, 2004 Mowry Road - Site Number: 8400005, Gainesville, Florida, United States
- University of South Florida - Neuromuscular Research, 13330 USF Laurel Drive - Site Number: 8400001, Tampa, Florida, United States
- Columbia University Medical Center - Neurological Institute, 710 W. 168th, 2nd floor, suite 204 - Site Number : 8400003, New York, New York, United States
- Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190 - Site Number: 0320001, Buenos Aires, Argentina
- Investigational Site Number : 0360001, Brisbane, Queensland, Australia
- The Montreal Neurological Institute and Hospital, 3801 rue University - Site Number: 1240001, Montreal, Quebec, Canada
- Investigational Site Number : 3760002, Ramat Gan, Israel
- Investigational Site Number : 8260002, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06844214 on ClinicalTrials.govOther trials for Proximal myotonic myopathy
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT06549400An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.Lupin Ltd.
- RECRUITINGNANCT06716931Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)Massachusetts General Hospital
- RECRUITINGPHASE3NCT06523400The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2Lupin Ltd.
- RECRUITINGNCT05854433Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2Wake Forest University Health Sciences
- RECRUITINGNCT04003363The United Kingdom National Registry for Myotonic DystrophyNewcastle University
- RECRUITINGNCT02398786Myotonic Dystrophy Family RegistryMyotonic Dystrophy Foundation
- RECRUITINGNCT00082108Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryUniversity of Rochester